Search research articles
Contact Us
Filters
Showing results (551-560 of 4,678) with videos related to
Page
of 468
Sort By:
Cancer Discovery
|
August 9, 2014
Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma
Alexander Stoeck, Serguei Lejnine, Andrew Truong, et al.
Cancer Discovery
|
May 10, 2013
Two drugs deemed breakthrough therapies
Cancer Discovery
|
May 10, 2013
Two is better than one: combining IGF1R and MEK blockade as a promising novel treatment strategy against KRAS-mutant lung cancer
Ron Chen, E Alejandro Sweet-Cordero
Cancer Discovery
|
April 26, 2013
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors
Erick J Morris, Sharda Jha, Clifford R Restaino, et al.
Cancer Discovery
|
April 3, 2013
GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB
Deepali Bang, Willie Wilson, Meagan Ryan, et al.
Cancer Discovery
|
April 4, 2013
The basic principles of chimeric antigen receptor design
Michel Sadelain, Renier Brentjens, Isabelle Rivière
Cancer Discovery
|
March 5, 2013
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer
Miriam Molina-Arcas, David C Hancock, Clare Sheridan, et al.
Cancer Discovery
|
February 13, 2013
Mitotic control of cancer stem cells
Monica Venere, Tyler E Miller, Jeremy N Rich
Cancer Discovery
|
March 9, 2013
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia
Takaomi Sanda, Jeffrey W Tyner, Alejandro Gutierrez, et al.
Cancer Discovery
|
March 12, 2013
Q&A: Rajeshwari Sridhara, Robert Temple on trial design. Interviewed by Suzanne Rose
Rajeshwari Sridhara, Robert Temple
Page
of 468
Search research articles
Search
Showing results (551-560 of 4,678) with videos related to
Sort By:
Page
of 468
Cancer Discovery
|
August 9, 2014
Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma
Alexander Stoeck, Serguei Lejnine, Andrew Truong, et al.
Cancer Discovery
|
May 10, 2013
Two drugs deemed breakthrough therapies
Cancer Discovery
|
May 10, 2013
Two is better than one: combining IGF1R and MEK blockade as a promising novel treatment strategy against KRAS-mutant lung cancer
Ron Chen, E Alejandro Sweet-Cordero
Cancer Discovery
|
April 26, 2013
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors
Erick J Morris, Sharda Jha, Clifford R Restaino, et al.
Cancer Discovery
|
April 3, 2013
GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB
Deepali Bang, Willie Wilson, Meagan Ryan, et al.
Cancer Discovery
|
April 4, 2013
The basic principles of chimeric antigen receptor design
Michel Sadelain, Renier Brentjens, Isabelle Rivière
Cancer Discovery
|
March 5, 2013
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer
Miriam Molina-Arcas, David C Hancock, Clare Sheridan, et al.
Cancer Discovery
|
February 13, 2013
Mitotic control of cancer stem cells
Monica Venere, Tyler E Miller, Jeremy N Rich
Cancer Discovery
|
March 9, 2013
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia
Takaomi Sanda, Jeffrey W Tyner, Alejandro Gutierrez, et al.
Cancer Discovery
|
March 12, 2013
Q&A: Rajeshwari Sridhara, Robert Temple on trial design. Interviewed by Suzanne Rose
Rajeshwari Sridhara, Robert Temple
Page
of 468